Rak Szyjki Macicy : Bibliografia - przypisy : HPV, szczepienia, profilaktyka

raport

Bibliografia - przypisy

¹ Bosch F. X., de Sanjose S., Rozdział 1: Human Papillomavirus and Cervical Cancer-Burden and Assessment of Causality. J Natl Cancer InstMonogr. 2003; 31: 3-13.² World Health Organisation. State of the art new vaccines research and development: Initiative for Vaccine Research. Geneva, Switzerland: World Health Organization. 2003: 1-74.
³ Jansen K., Shaw A., Human Papillomavirus Vaccines and Prevention of Cervical Cancer. Annual Review of Medicine. 2004; 55: 319-31.
⁴ Rak szyjkimacicy. http://www.hpv.pl/rak/archiwum/6051.html [stan na 14.03.2007]
⁵Centers for Disease Control and Prevention. Births: Final data for 2002. National Vital Statistics Reports, 2003; 52: 1-116. http://www.cdc.gov/nchs/data/nvsr/nvsr52/nvsr52_10.pdf.
⁶ National Cancer Institute. Cervical Cancer. http://women.cancer.gov/planning/whr0001/cervical.shtml.
⁷ Kotarski J., Didakowska J., Nowakowski A., Spaczyński M., Zdrowie prokreacyjne i jego zagrożenia, w: T. Niemiec (red.), Raport: Zdrowie kobiet w wieku prokreacyjnym15-49 lat. ProgramNarodów Zjednoczonych ds. Rozwoju. Warszawa. 2007: 135-137.
⁸ Parkin D., Bray F., Ferlay J., et al., Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
⁹ Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie. Nowotwory Złośliwe w Polsce w 2002 roku. Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, Warszawa 2004
¹⁰ Moore D., Cervical cancer. Obstet Gynecol. 2006; 107: 1152-1161.
¹¹ Stan zdrowia ludności Polski w przekroju terytorialnym w 2004 roku. Warszawa. GUS. 2007.
¹² Double Helix Quantitative Market Research, conducted on behalf of Glaxo Smith Kline. August 2005.
¹³ Stan zdrowia ludności Polski, op. cit.
¹⁴ Ostrowska A., Zróżnicowanie społeczne a zdrowie. Wyniki badań Warszawskich (w druku).
¹⁵ Kotarski J. i in. op. cit.
¹⁶ Lane D. S., Evans D., Measures andmethods in evaluating patient education programs for chronic illness. Medical Care. 1979, t. 1; Macintyre S., Gender differences in the perception of symptoms. Social Science and Medicine. 1993, t. 1.
¹⁷ Wronkowski Z., Brużewicz S., Problemy seksualne kobiet po leczeniu nowotworów, w: A. Ostrowska (red.), O seksualności osób niepełnosprawnych. Warszawa: Instytut Rozwoju Służb Społecznych. 2007.
¹⁸ Majewski S., Młynarczyk B., Choroby przenoszone drogą płciową, w: T. Niemiec (red.), Raport... op. cit.
¹⁹ Ostrowska A., Seksualność osób niepełnosprawnych, w: A. Ostrowska (red.), O seksualności osób... op. cit.
²⁰ Namysłowska I., Kobieta w cyklu życia rodziny, w: J. Meder (red.), Problemy zdrowia psychicznego kobiet. Kraków: Polskie Towarzystwo Psychiatryczne. 2003.
²¹ Hinton J., Dying. London. 1967; Benton R. J., Heath and Dying. NewYork. 1978; Ostrowska A., Śmierć w doświadczeniu jednostki i społeczeństwa. Warszawa: Wydawnictwo IFiS PAN. 2005.
²² Ostrowska A., Sikorska J., Gąciarz B., Osoby niepełnosprawne w Polsce w latach dziewięćdziesiątych. Warszawa: Instytut Spraw Publicznych. 2001; Kawczyńska-Butrym Z., op. cit.
²³ Kawczyńska-Butrym Z., Zmiany w rodzinie pod wpływem choroby, w: A. Firkowska-Mankiewicz (red.), Rodzina a problemy zdrowia i choroby. Warszawa: CPBP. 1990; Tobiasz-Adamczyk B., Wybrane elementy socjologii zdrowia i choroby. Kraków. Collegium Medium UJ. 2000.
²⁴ Frątczak E., Zmiany w poziomie płodności kobiet w Polsce, w: K. T. Niemiec, B. Balińska, Zdrowie reprodukcyjne w Polsce – stan obecny i perspektywy rozwoju. Warszawa. 2002.
²⁵ You Hetal., Multiple Human Papillomavirus Types Replicate in 3A Trophoblast, Placenta (2007).
²⁶ Brown M. L., Lipscomb J., Snyder C., The burden of illness of cancer: economic cost and quality of life. Annual Review of Public Health. 2001; 22: 91–113.
²⁷ Janerich D. T., Hadjimichael O., Schwartz P. E., et al., The screening histories of women with invasive cervical cancer. Connecticut. Am J Public Health. 1995; 85: 791-794.
²⁸ Insinga R. P., Glass A. G., Rush B.B., The health care costs of cervical human papillomavirus—related disease. AmJ Obstet Gynecol. 2004; 191: 114-120.
²⁹ Obliczeń dokonał dr n.med. Jerzy Jakubowicz z Kliniki Ginekologii Onkologicznej, Centrum Onkologii w Krakowie.
³⁰ Wronkowski Z., Zwierko M., Zasady i wyniki „Programu modelowego skryningu raka piersi i szyjkimacicy w Polsce, 1999-2000”. Nowotwory. 2002; vol. 52, suplement 2.
³¹ Goldie S. J., Gaffikin L., Goldhaber-Fiebert J. D., et al., Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries. NEJM. 2005; 353: 2158-2168.
³²Ries LAG, Harkins D., Krapcho M., et al., SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute. 2006. dostępne: http://seer.cancer.gov/csr/1975_2003. Rak szyjki macicy – problem medyczny, społeczny, ekonomiczny 51.
³³ Ferlay J., Bray F., Pisani P., et al., Cancer incidence,mortality and prevalence. Worldwide IARC Cancer Base 2004.
³⁴ Burchell A. N., Winer R. L., Sanjose S., et al., Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006; 24S3: S52-S61.
³⁵ Burchell A. N., Winer R. L., Sanjose S., et al., Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006; 24S3: S52-S61.
³⁶ Majewski S., Jablonska S., Human papillomavirus-associated tumors of the skin andmucosa. J AmAcad Dermatol. 1997; 36: 659-685.
³⁷ Bosch F. X., de Sanjose S., Chapter 1: Human papiloomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer InstMonogr. 2003; 31: 3-13.
³⁸ Muñoz N., Castellsaguèx., de González A. B., et al., HPV in the etiology of human cancer. Vaccine. 2006; 24S3: S1-S10.
³⁹ Clifford G. M., Rana R. K., Franceschi S., et al., Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1157-64.
⁴⁰ Majewski S., Pniewski T., Goyal-Stec M., Rola wirusów brodawczaka ludzkiego w rozwoju zmian łagodnych i złośliwych okolicy narządów płciowych. Zakażenia. 2005; 6: 58-62.
⁴¹Bosch F., Manos M., Munoz N., et al., Prevalence of human papillomavirus in cervical cancer: a woldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87: 796-802.
⁴²Woodman C., Collins S., Winter H., et al., Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001; 357: 1831-1836.
⁴³ Rozendaal L.,Westerga J., van der Linden J., et al., PCR based high risk HPV testing is superior to neutral network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol. 2000; 53: 606-611.
⁴⁴ Zieliński G., Snijders P., Rozendal L., et al., HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer. 2001; 85: 398-404.
⁴⁵ Nobbenhius M., Helmerhorst T., van den Brule A., et al., Cytological regression and clearance of high-risk human papillomavirus in women with abnormal cervical smear. Lancet. 2001; 358: 1782-1783.
⁴⁶ Benedet J. L., Anderson G. H., Stage IA carcinoma of the cervix revisited. Obstet Gynecol. 1996; 87: 1052-1059.
⁴⁷ Plante M., Renaud M. C., Francois H., et al., Vaginal radical trachelectomy: an oncologically safe fertility preserving surgery. An updated series of 72 cases and revive of the literature. Gynecol Oncol. 2004; 94: 614-623.
⁴⁸ Leitao M. M., Chi D. S., Fertility Sparing options for patients with gynecologicmalignancies. The Oncologyst. 2005; 10: 613-622.
⁴⁹ Monk B. J., Tian C., Rose P. G., et al., Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two GOG trials. Gynecol Oncol. 2007; 105: 427-433.
⁵⁰ Rose P. G., Chemoradiotherapy: The new standard care for invasive cervical cancer. Drugs. 2000; 60: 1239-1244.
⁵¹ Long H. J.3rd, Bundy B. N., Grendys E. C. Jr, et al., Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a GOG Study. J Clin Oncol. 2005; 23: 4626-4633.
⁵² International Federation of Gynacelogy and Obstetrics: 26th annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstem. 2006; 95 (suppl 1): S43-S103.
⁵³ Wypowiedź prof. Cezarego Szczylika, szefa kliniki onkologii Centralnego Szpitala Klinicznego Wojskowej Akademii Medycznej dla Dziennika, „Mało pieniędzy na raka”. 6.10.2007.
⁵⁴ „Mało pieniędzy na raka”, op. cit.
⁵⁵PublicHealthAgencyofCanada.Canadian human papilloma virus vaccinere search priorities workshop: final report. Can Commun Dis Rep. 2006;32SI:1-66.
⁵⁶ Del Priore G., Gilmore P., Maag T., et al., Colposcopic biopsies versus loop electrosurgical excision procedure cone histology in human immunod eficiency virus-positive women. J Reprod Med. 1996; 41: 653-657.
⁵⁷ US Food and Drug Administration. New Devices Aimed at Improving Pap Accuracy. October 1996. FDA Consumer Publication No(FDA) 97-4264.
⁵⁸US Department of Health and Human Services. National Institute of Health. National Cancer Institutes. Cancer Facts. The Pap Test: Questions and Answers. http://cis.nci.nih.gov/fact/5_16.htm.
⁵⁹ Saslow D., Runowicz C., Solomon D., et al., American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342-362.
⁶⁰ Agency for Health Care Policy and Research Recommendations and Rationale of Screening for Cervical Cancer U.S. Preventive Services Task Force (USPSTF). Dnia: 2007.05.10.
⁶¹ Nanda K., McCrory D., Myers E., et al., Accuracy of the Papanicolaou test in screening for and follow-up of cervical abnormalities: a systematic review. Ann Intern Med. 2000; 132: 810-819.
⁶² Renshaw A., Rescreening in cervical cytology for quality control. When bad data is worse than no data or what works, what doesn’t, and why. Clin Lab Med. 2003; 23: 695-70.
⁶³ Kulasingam S. L., Kim J. J., Lawrence W. F., et al., Cost-Effectiveness Analysis Based on the Atypical Squamous Cells of Undetermined Signifi cance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst. 2006; 98: 92-100.
⁶⁴ Kim J. J., Wright T. C., Goldie S. J., Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France and Italy. J Natl Cancer Inst. 2005; 97: 888-95.
⁶⁵MountS.,PapilloJ., A study of 10,296 pediatrican dadolescent Papanicolaus mear diagnoses in northern New England. Pediatrics.1999;103:539-545.
⁶⁶ Clifford G., Gallus S., et al., Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366: 991-998.
⁶⁷ Ho G., Bierman R., Beardsley L., et al.,Natural history of cervicovaginal papillomavirus infection in youngwomen.NEngl JMed. 1998; 338: 423-428.
⁶⁸ Clifford G., Gallus S., et al., Worldwide distributione op. cit.
⁶⁹ TerrisM., Wilson F., Smith H., et al., Epidemiology of cancer of the cervix. V. The relationship of coitus to carcinoma of the cervix. Am J Public Heatlt Nations Health. 1967; 57: 840-847.
⁷⁰ Garib S., Feldman S., Hellerstein S., et al., Cervical cancer: screening recommendations, with algorithms, for managing women with abnormal Pap test results. Boston: Brigham and Women’s Hospital. 2002.
⁷¹SmithJ.,GreekJ.,Berringtonde Gonzales A., etal., Cervical cancer and use of hormonal contraceptives: asystematic review. Lancet. 2003;361:1159-1167.
⁷² Janicek M., Averette H., Cervical cancer: prevention, diagnosis and therapeutics. CA Cancer J Clin. 2001; 51: 92-114.
⁷³ Sood A., Cigarette smoking and cervical cancer:meta-analysis and critical review of recent studies. Am J Prev Med. 1991; 7: 208-213.
⁷⁴ Massad L., Riester K., Anastos K., et al., Prevalence and predictors of squamous cell abnormalities in papanicolaou smears fromwomen infected with HIV-1. Women’s Interagency HIV Study Group. J Acquir Immune Defic Syndr. 1999; 21: 33-41.
⁷⁵ Massad L., Riester K., Anastos K., et al., Prevalence and predictorse op. cit.
⁷⁶ Clifford G., Gallus S., et al., Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366: 991-998.
⁷⁷ Garib S., Feldman S., Hellerstein S., et al., Cervical cancer: screening recommendations, with algorithms, for managing women with abnormal Pap test results. Boston: Brigham and Women’s Hospital. 2002.
⁷⁸Ho G., Bierman R., Beardsley L., et al.,Natural history of cervicovaginal papillomavirus infection in youngwomen.NEngl JMed. 1998; 338: 423-428.
⁷⁹ Sigurdsson K., Trends in cervical intra-epithelial neoplasia in Iceland through 1995: evaluation of targeted age groups and screening intervals. Acta Obstet Gynecol Scand. 1999; 78: 486-492.
⁸⁰ Saslow D., Runowicz C., Solomon D., et al., American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342-362.
⁸¹Saslow D., Runowicz C., Solomon D., et al., American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342-362.
⁸² Wronkowski Z., Zwierno M., Zasady i wyniki „Program umodelowego skryningu raka piersi i raka szyjkimacicy w Polsce 1999 -2000”. Nowotwory. 2002; Vol. 52, Suplement 2: 38-79.
⁸³ Raport: Zdrowie kobiet w wieku prokreacyjnym15-49 lat. Polska 2006. Program Narodów Zjednoczonych do Spraw Rozwoju. Warszawa. 2007: 135-137.
⁸⁴ Editorial: Should HPV vaccines bemandatory for all adolescents? Lancet. 2006; 368: 1212.
⁸⁵Spaczyński M., Nowak-Markwitz E., Basta A., et al., Rekomendacje Polskiego Towarzystwa Ginekologicznego dotyczące szczepienia przeciwko zakażeniomHPV. Ginekol Pol. 2007; 78: 185-190.
⁸⁶Garland S. M., Hernandes-Avila M., Wheeler C. M., et al., Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356: 1928-43.
⁸⁷ The FUTURE II Study Group. Quadrivalent vaccine agains thuman papillomavirus to prevent high-gradecervical lesions.NEngl JMed. 2007; 356:1915-27.
⁸⁸ The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet. 2007; 369: 1861-68.
⁸⁹ Joura E. A., Leodolter S., Hernandes-AvilaM., et al., Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 viruslike-particle vaccine against high-grade vulvae and vaginal lesions. Lancet. 2007; 369: 1693-702.
⁹⁰ Garland S.M.,Hernandes-Avila M.,Wheeler C.M.,Quadrivalent vaccine against human papilloma virus to prevent anogenital diseases.NEngl JMed.2007; 356: 1928-43.
⁹¹ The FUTURE II Study Group. Quadrivalent vaccine against human papilloma virus to prevent high-grade cervical lesions. NEngl JMed.2007; 356:1915-27.
⁹² The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet. 2007; 369: 1861-68.
⁹³ Joura E. A., Leodolter S., Hernandes-AvilaM., et al., Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 viruslike-particle vaccine against high-grade vulvae and vaginal lesions. Lancet. 2007; 369: 1693-702.
⁹⁴ Garland S.M.,Hernandes-Avila M.,Wheeler C.M.,Quadrivalent vaccine against human papilloma virus to prevent anogenital diseases.NEngl JMed.2007; 356: 1928-43.
⁹⁵ The FUTURE II Study Group. Quadrivalent vaccine against human papilloma virus to prevent high-gradecervical lesions. NEngl JMed.2007; 356:1915-27.
⁹⁶ Wright T. C., Bosch F. X., Franco E. L., Cuzick J., Schiller J. T., Garnett G. P.,Meheus A., HPV vaccines and screening in the prevention of cervical cancer; conclusions froma 2006 workshop of international experts. Vaccine. 2006; 24S3: 251-261.
⁹⁷ Woodman C.B.,Collins S.,Winter H.etal., Natural historyof cervical human papilloma virus infection in young women: along itudinal cohort study.Lancet. 2001; 357: 1831-1836.
⁹⁸ Garland S.M., Hernandes-Avila M., Wheeler C.M., Quadrivalent vaccine against human papilloma virus to prevent anogenital diseases.NEngl JMed.2007; 356: 1928-43.
⁹⁹ Lacey J. N., Lowndes C. M., Shah K. V., Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006; 24S3: S35-S41.
¹⁰⁰ Olsson S. E., Villa L. L., Costa R. L. R., et al., Induction of immune memory following administration of a prophylactic quadrivalent human papillo mavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007; 25: 4931-4939.
¹⁰¹ Villa L. L., Costa R. L. R., Petta C. A., et al., High sustained efficacy of prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 viruslike particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95: 1459-1466.
¹⁰² Paavonen J., Jenkins D., Bosch F. X., et. al., Efficacy of a prophylactic adjuvanted bivalent L1 virus-likeparticle vaccine against infection with human papillomavirus types 16 and 18 in young women. Lancet. 2007; 369: 2161-70.
¹⁰³ Harper D. M., Franco E. L., Wheeler C. M., et al., Sustained efficacy up to 4-5 years of a bivalent L1 viruslike particle vaccine against human papilloma virus types 16 and 18: follow-up from a randomized control trial. Lancet. 2006; 367: 1247-55.
¹⁰⁴ Baseman J. G., Koutsky L. A., The epidemiology of human papillomavirus infections. J. Clin. Virol. 2005; 32S1: S16-S24.
¹⁰⁵ Kimman T. G., Boot H. J., Berbers G. A.M., Bondt P. E. V., De Wit G. A., DeMelker H. E., Developing a vaccination evaluationmodel to support evidencebased decisionmaking on national immunization programs. Vaccine. 2006; 24: 4769-4778.
¹⁰⁶ Middleman A. B., Rosenthal S. L., Rickert V. I., Neinstein L., Fishbein D. B., D’Angelo L., Adolescent immunizations: A position paper of the Society for Adolescent Medicine. Journal of Adolescent Health. 2006; 38: 321-327.
¹⁰⁷ Zimmerman R. K., Ethical analysis of HPV vaccine policy options. Vaccine. 2006; 24: 4812-4820.
¹⁰⁸ Brabin L., Roberts S. A., Farzaneh F., Kitchener H. C., Future acceptance of adolescent human papillomavirus vaccination: A survey of parental attitudes. Vaccine. 2006; 24: 3087-3094.
¹⁰⁹ Giles M., Garland S., A study of women’s knowledge regarding human papillomavirus infection, cervical cancer and human papillomavirus vaccines. Austr New Zea J Obstet Gynaecol. 2006; 46: 311-315.
¹¹⁰ Informacja PAP z dnia 20.09.2007.
¹¹¹Kotarski J., Didkowska J., Nowakowski A., Spaczyński M., Zdrowie prokreacyjne i jego zagrożenia, w: Raport: Zdrowie kobiet... op. cit.
¹¹²Majewski S., Sikorski M., Rekomendacje Polskiego Towarzystwa Profilaktyki Zakażeń HPV dotyczące stosowania czterowalentnej szczepionki profilaktycznej przeciw HPV typów 6, 11, 16, 18. Przew Lek. 2007; 10:120-124.
¹¹³ Franco E., Bosch F., Cuzick J., et al., Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine. 2006; 24S3: S242-S249.
¹¹⁴ Izdebski Z., Ostrowska A., Seks po polsku. Zachowania seksualne jako element stylu życia Polaków. Warszawa: Muza. 2003.
¹¹⁵ Raport: Poziom życia Polaków. Warszawa: CBOS. 2004; Raport: Oceny sytuacji materialnej. Warszawa: CBOS. 2000.
¹¹⁶ Tackling Heath inequalities in Europe: an Integrated Approach Rotterdam. Department of PublicHealth, University Medical Center Rotterdam. 2007.
¹¹⁷ Golinowska S., i in., Opieka zdrowotna w Polsce po reformie. Warszawa. CASE. 2002.
¹¹⁸ Ronco G., Segnan N., Giordano L., i in., Interaction of spontaneus and organised screening for cervical cancer in Turin, Italy. Eur.J Cancer 1997; 33: 1262-1267.
¹¹⁹ Piątkowski W., Zdrowie i chorobaw rodzinach chłopskich, w: A. Firkowska-Mankiewicz (red.), Rodzina a problemy zdrowia i choroby. Warszawa.CPBP.1990.
¹²⁰ Tobiasz-Adamczyk B., Relacje lekarz-pacjent w perspektywie socjologiimedycyny. Kraków. Wydawnictwo UJ. 2002.
¹²¹ Ostrowska A., Paternalizm czy partnerstwo? w: H.Domański, A.Ostrowska, P. Sztabiński (red.), W środku Europy? Warszawa. Wydawnictwo IFiS PAN. 2006, str. 185-200.
¹²² Izdebski Z., Ostrowska A., Seks po polsku. Zachowania seksualne jako element stylu życia Polaków. Warszawa. Muza. 2003.
¹²³ Izdebski Z., Ryzykowna dekada: seksualność Polaków w dobie HIV/AIDS. Studium porównawcze 1997-2001-2005. Zielona Góra. Oficyna Wydawnicza Uniwersytetu Zielonogórskiego. 2006.
¹²⁴ BeckerM., Psychosocial aspects of health – related behaviour, w: H. Freeman, S. Levine, L. Reeder (red.), Handbook ofmedical sociology, 3rd, ed. Englewood Cliffs, N.J.: Prentice Hall, str. 253-274.
¹²⁵ Wypowiedź Głównego Inspektora Sanitarnego na konferencji „Rak szyjki macicy–problem medyczny, społeczny, ekonomiczny”. Warszawa, 9.10.2007.
¹²⁶ Golinowska S., et. al., Opieka zdrowotna w Polsce po reformie. Warszawa: CASE. 2002, str. 144-160.
¹²⁷ Double Helix... op. cit.
¹²⁸ Bayer Schering Pharma: Ogólnoeuropejskie badania dotyczące stosowania środków antykoncepcyjnych. Polska na tle Europy. Warszawa. 2007.
¹²⁹ Sprawozdanie roczne z wykonania budżetów jednostek samorządu terytorialnego za 2006r. (dostępne nastronie internetowej Ministerstwa Finansów).